Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
South Korea
· Delayed Price · Currency is KRW 127,000
+1,900 (1.52%)
Mar 9, 2026, 3:30 PM KST
Mezzion Pharma Revenue
Mezzion Pharma had revenue of 2.13B KRW in the quarter ending September 30, 2025, a decrease of -5.89%. This brings the company's revenue in the last twelve months to 7.75B, down -44.95% year-over-year. In the year 2024, Mezzion Pharma had annual revenue of 8.61B, down -72.85%.
Revenue (ttm)
7.75B
Revenue Growth
-44.95%
P/S Ratio
497.89
Revenue / Employee
430.53M
Employees
18
Market Cap
3,858.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.61B | -23.11B | -72.85% |
| Dec 31, 2023 | 31.72B | 994.76M | 3.24% |
| Dec 31, 2022 | 30.73B | 4.07B | 15.28% |
| Dec 31, 2021 | 26.65B | -1.98B | -6.92% |
| Dec 31, 2020 | 28.63B | 10.71B | 59.79% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,556.97B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| Sam Chun Dang Pharm. | 220.74B |
| OliX Pharmaceuticals | 10.18B |
| D&D Pharmatech | 8.36B |
| CLASSYS | 336.80B |
| PharmaResearch | 496.03B |